Blixeprodil vs SP-101

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

Blixeprodil

Developed by Gilgamesh Pharma

Phase 2 in Major Depressive Disordersmall molecule
Weak signal

NCT06309277 · Phase 2 · completed

This two-part, randomized, quadruple-blind, placebo-controlled Phase 2a study gave single and multiple oral doses of GM-1020 (blixeprodil) or placebo to 46 patients with major depressive disorder. The only registered primary outcome is the incidence of treatment-emergent adverse events, which has no formal efficacy test, so there is no met or missed result. Antidepressant response was a preliminary, non-primary aim. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment Emergent Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Incidence of Treatment Emergent Adverse Events (Baseline, Day 29): Primary outcome, incidence of treatment-emergent adverse events to Day 29 (no formal efficacy test): Part A, 23 participants on placebo and 43 on GM-1020 140 mg with at least one TEAE (CT.gov posted results). (not_applicable)

Result source: NCT06309277

SP-101

Developed by Synphatec (Shanghai) Biopharmaceutical

Phase 1 in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBlixeprodilSP-101
MADRS, change (acute)-10.5 vs -5.4−5.1 vs placebo140 mg · wk 1.14 · n 24NCT06309277
1 other result
  • -12.1 vs -5.8 140 mg · wk 0.14 · n 25 · Phase 2 · secondary NCT06309277
—Not reported
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported—Not reported
MADRS remission—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

Blixeprodil
-10.5 vs -5.4−5.1 vs placebo140 mg · wk 1.14 · n 24NCT06309277
1 other result
  • -12.1 vs -5.8 140 mg · wk 0.14 · n 25 · Phase 2 · secondary NCT06309277
SP-101
—Not reported

CGI-S, change (acute)

Blixeprodil
—Not reported
SP-101
—Not reported

MADRS response

Blixeprodil
—Not reported
SP-101
—Not reported

MADRS remission

Blixeprodil
—Not reported
SP-101
—Not reported

Relapse (% of patients)

Blixeprodil
—Not reported
SP-101
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SP-101: no structured comparison results are available for Major Depressive Disorder.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Blixeprodil: 2 of 4 rows · SP-101: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBlixeprodil
Dropout rate
—210 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
—140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
—140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Discontinued due to AEs
—210 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
—140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
—140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Serious AEs
0%210 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Most frequent reported AEs
210 mg
time perception altered 63.2% (placebo 0%)
euphoric mood 57.9% (placebo 0%)
hallucination, visual 57.9% (placebo 0%)
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
140 mg
dizziness 46.5% (placebo 4.5%)
euphoric mood 44.2% (placebo 0%)
headache 37.2% (placebo 18.2%)
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
140 mg
euphoric mood 61.1% (placebo 0%)
dizziness 50% (placebo 4.5%)
headache 50% (placebo 18.2%)
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Blixeprodil

MADRS -12.138 vs -5.85 placebo score @ 0.14wk140 mg
absolute change · score
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 1 more result
-10.467 vs -5.386 placebo score @ 1.14wk140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Blixeprodil's landscape · SP-101's landscape